POM-V Prescription Required

Meflosyl 5% Solution for Injection

Active ingredient: Flunixin

Form

Injection

Species

Horses

Manufacturer

Zoetis UK Limited

VMD MA No.

42058/5225

What it's used for

For the alleviation of inflammation and pain associated with musculo- skeletal disorders and for the alleviation of visceral pain associated with colic.

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Flunixin

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Meflosyl 5% Solution for Injection — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 26 Mar 2026.

For the alleviation of inflammation and pain associated with musculo-
skeletal disorders and for the alleviation of visceral pain associated with
colic.

For intravenous administration.
For use in musculo-skeletal disorders, the recommended dose rate is 1.1
mg flunixin/kg bodyweight, equivalent to 1 ml per 45 kg, once daily for up
to 5 days depending on clinical response.
For use in equine colic, the recommended dose rate is 1.1 mg flunixin/kg
bodyweight, equivalent to 1 ml per 45 kg. Treatment may be repeated once
or twice if colic recurs.
For the treatment of endotoxaemia or shock-associated with gastric torsion
and with other conditions in which the circulation of blood to the gastro-
intestinal tract is compromised: 0.25 mg/kg (= 1 ml per 200 kg bodyweight)
administered every 6-8 hours.

Do not exceed the recommended dose or duration of treatment.
Do not administer to pregnant mares.
Do not use in known cases of hypersensitivity to the active substance or to
any of the excipients.
Do not use in animals suffering from cardiac, hepatic or renal disease,
where there is a possibility of gastro-intestinal ulceration or bleeding.

Flunixin meglumine is a non-steroidal anti-inflammatory drug (NSAID).
Untoward effects include gastro-intestinal irritation, ulceration and in
dehydrated or hypovolaemic animals, potential for renal damage.
In very rare cases allergic reactions (anaphylaxis) may occur after
administration of the veterinary medicinal product.
The frequency of adverse reactions is defined using the following
convention:
- very common (more than 1 in 10 animals displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals
treated)

Revised: December 2025
MA split from NI Expiry following AN: 02974/2025
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated
reports).

Non steroidal anti-inflammatory drugs are not permitted under the Rules of
Racing and under rules governing other competitive events. The Royal

Revised: December 2025
MA split from NI Expiry following AN: 02974/2025
College of Veterinary Surgeons has given advice to the veterinary
profession regarding the use of anti-inflammatory drugs in competing
horses. It states that if a veterinarian recommends the discontinuation of
any such drug less than 8 days before racing, he should feel sure that he
has catered for all but the most exceptional case.

i) Special precautions for use in animals
Intra-arterial injection should be avoided.
Use in any animal less than 6 weeks of age or in aged animals may involve
additional risk. If such use cannot be avoided, animals may require a
reduced dosage and careful clinical management.
Avoid use in hypovolaemic animals, except in the case of endotoxaemia or
septic shock.
It is preferable that NSAIDs which inhibit prostaglandin synthesis are not
administered to animals undergoing general anaesthesia until fully
recovered.
Flunixin is toxic to avian scavengers. Do not administer to animals
susceptible to enter wild fauna food chain. In case of death or sacrifice of
treated animals, ensure that they are not made available to wild fauna.
ii) Special precautions to be taken by the person administering the veterinary
medicinal product to animals
Flunixin meglumine is a non-steroidal anti-inflammatory drug (NSAID). The
product may cause an allergic reaction in people sensitised to NSAIDs.
People with known hypersensitivity to NSAIDs should avoid contact with
the product. Hypersensitivity reactions may be serious.
To avoid possible sensitisation reactions and/or skin irritation, avoid contact
with skin. Gloves should be worn during application. Wash hands after
use. In case of accidental self-injection, seek medical advice immediately
and show the package leaflet or the label to the physician.
This product may cause eye irritation. Avoid contact with eyes. In the case
of accidental contact with eyes, rinse immediately with plenty of water and
seek medical advice.

interaction
Monitoring of drug compatibility is required in case of adjunctive therapy.
Do not administer other non-steroidal anti-inflammatory drugs (NSAIDs)
concurrently or within 24 hours of each other. Some NSAIDs may be highly
bound to plasma proteins and compete with other highly bound drugs which
can lead to toxic effects.
Concurrent administration of potentially nephrotoxic drugs should be
avoided.

Do not store above 25°C.
Protect from light
Following withdrawal of the first dose use the product within 28 days.
Discard unused product.

Not to be used in horses intended for human consumption.
Treated horses may never be slaughtered for human consumption.
The horse must have been declared as not intended for human
consumption under national horse passport legislation.

Revised: December 2025
MA split from NI Expiry following AN: 02974/2025
5.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.